by admin
Share
Dear Investors,
I have received several inquiries about our October 8th press release. It marks an exciting and historic milestone for Ocumetics. The patients selected for our first clinical group entered the study with very poor functional vision due to cataracts and were struggling to see clearly at distance.
One month following cataract surgery and implantation of the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”), their vision has improved dramatically to 20/40 or better, an extraordinary outcome at this early stage.
It’s important to note that patients must continue to heal and adapt after cataract surgery, and best vision typically develops over three to six months. The fact that our participants are seeing this level of improvement so soon after surgery is remarkable in its speed, while still aligning with the expected course of visual recovery.
These outcomes reinforce the safety, performance, and promise of the Ocumetics Lens. They demonstrate that our technology is behaving exactly as designed, offering patients the potential for clear, natural vision across all distances.
We invite you to read the October 8th press release for details, but in summary:
- The safety profile remains excellent.
- Surgical handling and implantation have been both smooth and reproducible.
- Patients with previously poor vision are now experiencing clear, functional sight and improvement is expected to continue.
This is tremendous news for Ocumetics, for our partners, and most importantly for patients worldwide who dream of life without glasses or contacts. We are building momentum, and I am more confident than ever that Ocumetics is redefining the future of vision.
Warm regards,
Dean Burns
President & CEO
Ocumetics Technology Corp.
Key Highlights Early First-in-Human clinical results have drawn the attention of industry leaders and several of the largest vision care technology companies in the world. Ocumetics will leverage the conference to further engage with global strategic partners to accelerate development and commercialization efforts. Calgary, Canada – TheNewswire – April 1, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSV:V OTC) (OTCQB: OTCFF) (FRA:
Key Highlights Breakthrough Accommodating Interocular Lens Design: The enhanced lens design introduces several novel concepts that are expected to improve substantially upon the consistency, durability, and manufacturability of the lens. Enhanced Performance with Greater Reliability: This next-generation technology is anticipated to deliver natural optical responsiveness and improved mechanical stability, supporting excellent vision across its full
Calgary, Alberta – February 10, 2026 – TheNewswire – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is pleased to announce that the Corporation has entered into a forbearance agreement with the holders of secured convertible debentures (the “Debentures”) that were issued by the Corporation in May and June 2024 (see press release
